Research Paper Volume 16, Issue 6 pp 5618—5633
Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy
Figure 2. Hub genes selected to construct the risk model. (A, B) LASSO analysis for hub genes associated with the survival rate of glioma patients with TERTp mutations. (C) Multivariate Cox regression analysis of HOXC6, WT1, CD70, and OTP. These four genes were used to construct the risk model.